TP taps Almac to develop repotrectinib pan-cancer companion diagnostic

test tubes
TP raised $80 million to move repotrectinib into phase 2 testing early next year. (Pixabay)

TP Therapeutics and Almac Diagnostic Services have launched a global collaboration to develop a pan-cancer companion diagnostic test for TP’s repotrectinib, aimed at drug-resistant tumors with ROS1, NTRK1-3 and ALK mutations.

Almac will develop the next-generation sequencing diagnostic on ArcherDx’s Anchored Multiplex PCR platform, and plans to submit it to the FDA for approval in guiding the selection of patients for repotrectinib treatment from its laboratory in Durham, North Carolina. The financial terms of the deal were not disclosed.

“Almac provides us with deep experience in the development and regulatory approval of next-generation sequencing diagnostic assays, which will enable the selection of patients who may not otherwise have access to a targeted therapy like repotrectinib,” said J. Jean Cui, TP’s founder, president and chief scientific officer.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Almac Discovery, RCSI form anticancer stem cell R&D pact

TP raised $80 million earlier this month in a mezzanine funding round as it looks to move repotrectinib into phase 2 research in early 2019. In addition, the company is considering combination studies with EGFR inhibitors such as Tagrisso in patients that have seen their non-small cell lung cancer progress.

In addition, the company hopes to have three active clinical assets in its pipeline over the next 18 months, with IND filings for a dual CSF1R/MET inhibitor and an RET inhibitor program planned for the first and second halves of 2019, respectively.

Suggested Articles

Quest Diagnostics has launched three new test kits for STDs that consumers can order online, within the privacy of their own home.

Digital imaging analysis provider Aidoc has raised $27 million to help build out its go-to-market team, after processing its one-millionth CT scan.

Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.